Moreover, a GAS6-neutralizing antibody prevents the ability of MSCs-derived soluble factors to sustain MM survival by suppressing the NF-κB signaling pathway and IL-6 expression [36]. Here, NFKB1 is linked to Miyoshi myopathy.